Table 3 Associated risk factors with virological failure at the Tefera Hailu Memorial Hospital, Sekota, northeast Ethiopia, 2019

Age

10–19

5.78 (1.3–25.71)

4.39 (0.2–116.5)

20–29

1.73 (0.41–7.35)

2.87 (0.32–25.4

30–39

1.50 (0.41–5.52)

1.12 (0.16–7.72)

40–49

1.62 (0.43–6.08)

2.36 (0.35–15.9)

50 +

Education status

Not read/write

1.56 (0.4–6.13)

0.97 (0.094–83.03)

Primary

3.52 (1.0–12.43)

1.58 (0.195–12.9)

Secondary

2.97 (0.79–11.15)

2.19 (0.26–18.5)

Above secondary

Current ART regimen

1c

0.54 (0.13–2.28)

2.1 (0.09–48.9)

1d

0.21 (0.05–0.91)

0.4 (0.01–12.6)

1e

0.16 (0.04–0.64)

0.14 (0.003–5.6)

1f

0.179 (0.02–1.29)

0.33 (0.007–17.2)

4c

Baseline ART regimen

1a

0.24 (0.054–1.08)

0.29 (0.005–15.4)

1b

0.33 (0.09–1.24)

1.13 (0.02–76.0)

1c

0.37 (0.09–1.37)

0.39 (0.01–15.9)

1d

0.28 (0.08–0.97)

1.15 (0.02–65.5)

1e

0.15 (0.04–0.50)

1.18 (0.02–80.3)

4c

Current CD4 result

≤ 100

36.55 (9.9–94.77)

42.36 (7.43–79.6)

101–250

7.12 (2.33–21.8)

12.1 (2.76–53.1)

251–500

3.36 (1.03–10.96)

4.78 (1.15–19.77)

501 +

Current clinical stage

I

II

6.79 (2.82–16.34)

1.1 (0.09–13.3)

III

 6.79 (1.32–35.03)

3.15 (0.83–12.0)

Dose of ART per day

Once

0.49 (0.25–0.95)

0.48 (0.06–4.1)

Twice

Drug interruption

No

Yes

 3.30 (1.50–7.24)

1.19 (0.37–3.86)

Drug adherence

≥ 95%

< 95%

9.04 (4.37–18.7)

 6.36 (20.35–17.2)

Prophylaxis

No

Yes

 3.88 (10.18–12.77)

 5.42 (0.98–29.9)

TB history

Yes

1.86 (0.9–1.80)

1.53 (0.53–4.45)

No

Immunologic failure

No

Yes

7.63 (2.84–20.5)

0.06 (0.003–1.5)

Duration on ART (months)

6–24

0.13 (0.02–0.97)

0.48 (0.01–0.97)

25–48

0.41 (0.14–1.23)

0.37 (0.07–1.87)

49–72

0.50 (0.21–1.20)

0.24 (0.06–0.97)

73 +